JP2023544797A5 - - Google Patents

Info

Publication number
JP2023544797A5
JP2023544797A5 JP2023521295A JP2023521295A JP2023544797A5 JP 2023544797 A5 JP2023544797 A5 JP 2023544797A5 JP 2023521295 A JP2023521295 A JP 2023521295A JP 2023521295 A JP2023521295 A JP 2023521295A JP 2023544797 A5 JP2023544797 A5 JP 2023544797A5
Authority
JP
Japan
Prior art keywords
days
pharmaceutical composition
approximately
hours
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/053759 external-priority patent/WO2022076549A1/en
Publication of JP2023544797A publication Critical patent/JP2023544797A/ja
Publication of JP2023544797A5 publication Critical patent/JP2023544797A5/ja
Pending legal-status Critical Current

Links

JP2023521295A 2020-10-07 2021-10-06 脈絡膜上投与用の、高粘度製剤などの製剤 Pending JP2023544797A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063088826P 2020-10-07 2020-10-07
US63/088,826 2020-10-07
US202163147527P 2021-02-09 2021-02-09
US63/147,527 2021-02-09
PCT/US2021/053759 WO2022076549A1 (en) 2020-10-07 2021-10-06 Formulations for suprachoroidal administration such as high viscosity formulations

Publications (2)

Publication Number Publication Date
JP2023544797A JP2023544797A (ja) 2023-10-25
JP2023544797A5 true JP2023544797A5 (cg-RX-API-DMAC7.html) 2024-03-06

Family

ID=78516913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521295A Pending JP2023544797A (ja) 2020-10-07 2021-10-06 脈絡膜上投与用の、高粘度製剤などの製剤

Country Status (8)

Country Link
US (1) US20240024508A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225270A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023544797A (cg-RX-API-DMAC7.html)
AU (1) AU2021358048A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198372A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023004035A (cg-RX-API-DMAC7.html)
TW (1) TW202228648A (cg-RX-API-DMAC7.html)
WO (1) WO2022076549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202345913A (zh) * 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
EP4593955A1 (en) 2022-09-30 2025-08-06 RegenxBio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024238867A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2025217230A1 (en) 2024-04-08 2025-10-16 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2015316709B2 (en) 2014-09-19 2020-03-26 Oxular Limited Ophthalmic delivery device
JP2019515027A (ja) 2016-04-15 2019-06-06 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system

Similar Documents

Publication Publication Date Title
JP7733706B2 (ja) 血管新生眼疾患を処置するためのvegfアンタゴニストの使用
US20240024508A1 (en) Formulations for suprachoroidal administration such as high viscosity formulations
US20230414788A1 (en) Formulations for suprachoroidal administration such as gel formulations
US20230372538A1 (en) Formulations for suprachoroidal administration such as formulations with aggregate formation
EP4027983B1 (en) Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept
KR20240145489A (ko) 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 신생혈관 질환을 치료하는 방법
JP2024148177A (ja) アフリベルセプトをコードするaav2バリアントを使用する眼内血管新生疾患を処置する方法
Tu et al. AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization
US20250339555A1 (en) Formulations for suprachoroidal administration such as formulations with aggregate formation
US20260034243A1 (en) Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
CN116546975A (zh) 用于脉络膜上施用的制剂诸如高粘度制剂
CN116635004A (zh) 用于脉络膜上施用的制剂如凝胶制剂
CN116601299A (zh) 用于脉络膜上施用的制剂诸如具有聚集体形成的制剂
WO2023196835A1 (en) Formulations for suprachoroidal administration such as gel formulations
HK40077797B (en) Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept
HK40077797A (en) Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept